longer gleevec use extends gist patient survival
taking the novartis cancer drug gleevec for three years following surgery to remove gastrointestinal stromal tumors (gist) extended survival in more high-risk patients than the standard one year of gleevec treatment, according to data released on sunday.
http://feeds.reuters.com/~r/reuters/healthnews/~3/ioqa8un4cqy/us-cancer-gist-novartis-idustre7541cc20110605
20895
05 Jun 2011 15:27:46
reuters
health